Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation

View Full Paper
Ask AI
Bookmark
Share

Authors

AFAmir FathiDPDaniel A. PollyeaJMJames McCloskey

Discussion

Loading...

Member takes

Overview

Phase 1 study finds 77% complete remission in newly diagnosed Acute Myeloid Leukemia, suggesting promising outcomes with ivosidenib maintenance therapy.

Key Points

  • Overall complete remission rate was 77% among 60 patients receiving Ivosidenib with intensive chemotherapy.
  • Ivosidenib maintenance therapy demonstrated long-term benefits with manageable adverse events across treatment cycles.
  • Multicenter open label phase 1 trial assessed safety and response in patients with newly diagnosed acute myeloid leukemia.
  • Adding Ivosidenib enhances treatment options, particularly as a bridge to allogeneic hematopoietic stem cell transplantation.

Cite This Study

Fathi et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e379https://doi.org/10.1182/blood-2025-992
View Full Paper
Ask AI
Bookmark
Share